GlassScriptPhysician profile
Rose Shea
NPI 1801511217
$8,549.18
in general payments reported to CMS, 2019-2025
15 companies · $4,616 in 2025
The $4,616 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $946 · 2024: $2,987 · 2025: $4,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,265 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,265.21 |
| Education | $283.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,510.96 | 2023-2025 | Caplyta |
| Abbvie INC. | $1,374.43 | 2023-2025 | |
| Alkermes, INC. | $917.38 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $769.02 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $714.04 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $694.81 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $638.76 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $260.29 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $244.67 | 2024-2025 | Fanapt |
| Lundbeck LLC | $132.55 | 2025 | Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $84.72 | 2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $68.36 | 2023-2024 | Perseris, Sublocade |
| Gilead Sciences, INC. | $60.24 | 2024-2025 | |
| Corium, LLC | $53.05 | 2024-2025 | Azstarys |
| Uswm, LLC | $25.90 | 2024 | Lucemyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Shea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.